Matching articles for "Duchenne muscular dystrophy"
Issue 1718 · December 23, 2024
Givinostat (Duvyzat) for Duchenne Muscular Dystrophy

Givinostat ( Duvyzat – Italfarmaco), an oral histone deacetylase inhibitor, has been approved by the FDA for treatment of patients ≥6 years old with Duchenne muscular dystrophy (DMD), regardless of the…

Med Lett Drugs Ther. 2024 Dec 23; 66(1718):204-5 doi:10.58347/tml.2024.1718c
Givinostat ( Duvyzat – Italfarmaco), an oral histone deacetylase inhibitor, has been approved by the FDA for treatment of patients ≥6 years old with Duchenne muscular dystrophy (DMD), regardless of the DMD-causing mutation. It is the first nonsteroidal drug to be approved for this indication. The oral corticosteroids deflazacort (Emflaza) and vamorolone (Agamree) are also approved for treatment of patients with all genetic variants of DMD.
Issue 1709 · August 19, 2024 Free
In Brief: Expanded Indication for Elevidys

The adeno-associated virus (AAV) vector-based gene therapy delandistrogene moxeparvovec-rokl ( Elevidys – Sarepta) received accelerated approval from the FDA in 2023 for treatment of ambulatory children 4-5…

Med Lett Drugs Ther. 2024 Aug 19; 66(1709):135-6 doi:10.58347/tml.2024.1709e
The adeno-associated virus (AAV) vector-based gene therapy delandistrogene moxeparvovec-rokl ( Elevidys – Sarepta) received accelerated approval from the FDA in 2023 for treatment of ambulatory children 4-5 years old with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene. It has now received full approval for use in ambulatory patients ≥4 years old and accelerated approval for use in nonambulatory patients with DMD.
Issue 1686 · October 2, 2023
Delandistrogene Moxeparvovec (Elevidys) for Duchenne Muscular Dystrophy

Delandistrogene moxeparvovec-rokl ( Elevidys – Sarepta), an adeno-associated virus (AAV) vector-based gene therapy, has received accelerated approval from the FDA for treatment of ambulatory children 4-5…

Med Lett Drugs Ther. 2023 Oct 2; 65(1686):159-60 doi:10.58347/tml.2023.1686d
Delandistrogene moxeparvovec-rokl ( Elevidys – Sarepta), an adeno-associated virus (AAV) vector-based gene therapy, has received accelerated approval from the FDA for treatment of ambulatory children 4-5 years old with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene. It is the first gene therapy to be approved in the US for treatment of DMD. Accelerated approval was based on expression of microdystrophin in skeletal muscle, a surrogate endpoint.
Issue 1609 · October 19, 2020
Viltolarsen (Viltepso) for Duchenne Muscular Dystrophy

The antisense oligonucleotide viltolarsen ( Viltepso – NS Pharma) has received accelerated approval from the FDA for treatment of Duchenne muscular dystrophy (DMD) in patients who have mutations of the…

Med Lett Drugs Ther. 2020 Oct 19; 62(1609):167
The antisense oligonucleotide viltolarsen ( Viltepso – NS Pharma) has received accelerated approval from the FDA for treatment of Duchenne muscular dystrophy (DMD) in patients who have mutations of the dystrophin gene that are amenable to exon 53 skipping (DMD-53). It is the second drug to be approved for this indication; the antisense oligonucleotide golodirsen (Vyondys 53) was approved in 2019.
Issue 1603 · July 27, 2020
Golodirsen (Vyondys 53) for Duchenne Muscular Dystrophy

Golodirsen ( Vyondys 53 — Sarepta), an antisense oligonucleotide, has received accelerated approval from the FDA for treatment of Duchenne muscular dystrophy (DMD) in the ~8% of patients who have mutations…

Med Lett Drugs Ther. 2020 Jul 27; 62(1603):119-20
Golodirsen ( Vyondys 53 — Sarepta), an antisense oligonucleotide, has received accelerated approval from the FDA for treatment of Duchenne muscular dystrophy (DMD) in the ~8% of patients who have mutations of the dystrophin gene that are amenable to exon 53 skipping. It is the first drug to be approved for this indication and the third to be approved for treatment of DMD; the antisense oligonucleotide eteplirsen (Exondys 51) and the oral corticosteroid deflazacort (Emflaza) were approved earlier.
Issue 1529 · September 11, 2017
Deflazacort (Emflaza) for Duchenne Muscular Dystrophy

Deflazacort ( Emflaza – PTC Therapeutics), an oral corticosteroid, has been approved by the FDA for treatment of Duchenne muscular dystrophy (DMD) in patients ≥5 years old. It has been available outside…

Med Lett Drugs Ther. 2017 Sep 11; 59(1529):153-4
Deflazacort ( Emflaza – PTC Therapeutics), an oral corticosteroid, has been approved by the FDA for treatment of Duchenne muscular dystrophy (DMD) in patients ≥5 years old. It has been available outside the US for many years. Deflazacort is the second drug to be approved for treatment of DMD; eteplirsen (Exondys 51) , an antisense oligonucleotide approved for IV administration in patients with mutations of the dystrophin gene amenable to exon 51 skipping (about 13% of DMD cases), was the first.
Issue 1507 · November 7, 2016
Eteplirsen (Exondys 51) for Duchenne Muscular Dystrophy

Eteplirsen ( Exondys 51 – Sarepta), an antisense oligonucleotide, has received accelerated approval from the FDA for treatment of Duchenne muscular dystrophy (DMD) in patients who have a mutation of the…

Med Lett Drugs Ther. 2016 Nov 7; 58(1507):145-6
Eteplirsen ( Exondys 51 – Sarepta), an antisense oligonucleotide, has received accelerated approval from the FDA for treatment of Duchenne muscular dystrophy (DMD) in patients who have a mutation of the dystrophin gene that is amenable to exon 51 skipping. It is the first drug to be approved for treatment of DMD.